The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury
Guixian Liu,Jie Liang,Wei Li,Suli Jiang,Meiying Song,Shuo Xu,Qiaochu Du,Luoyang Wang,Xiao Wang,Xiaoli Liu,Lei Tang,Zijie Yang,Mengting Zhou,Haining Meng,Li Zhang,Yanyan Yang,Bei Zhang
DOI: https://doi.org/10.1016/j.intimp.2024.112452
2024-09-10
Abstract:Peripheral nerve injury seriously endangers human life and health, but there is no clinical drug for the treatment of peripheral nerve injury, so it is imperative to develop drugs to promote the repair of peripheral nerve injury. Erythropoietin (EPO) not only has the traditional role of promoting erythropoiesis, but also has a tissue-protective effect. Over the past few decades, researchers have confirmed that EPO has neuroprotective effects. However, side effects caused by long-term use of EPO limited its clinical application. Therefore, EPO derivatives with low side effects have been explored. Among them, ARA290 has shown significant protective effects on the nervous system, but the biggest disadvantage of ARA290, its short half-life, limits its application. To address the short half-life issue, the researchers modified ARA290 with thioether cyclization to generate a thioether cyclized helical B peptide (CHBP). ARA290 and CHBP have promising applications as peptide drugs. The neuroprotective effects they exhibit have attracted continuous exploration of their mechanisms of action. This article will review the research on the role of EPO, ARA290 and CHBP in the nervous system around this developmental process, and provide a certain reference for the subsequent research.